(Total Views: 494)
Posted On: 08/05/2020 1:01:10 PM
Post# of 154119
From the sounds of it, most will disagree, but I thought the WSJ was a positive development.
I agree it was more of a lifestyle piece about the risk/reward investing in the Covid bubble. But also about investor loyalty and enthusiasm.
The sheer number of mentions for Cytodyn and Leronlimab in the WSJ will attract more investors. The net result IMO is thousands more eyeballs are doing DD on Cytodyn today than yesterday.
As long as they’re talking about us. GLTA.
I agree it was more of a lifestyle piece about the risk/reward investing in the Covid bubble. But also about investor loyalty and enthusiasm.
The sheer number of mentions for Cytodyn and Leronlimab in the WSJ will attract more investors. The net result IMO is thousands more eyeballs are doing DD on Cytodyn today than yesterday.
As long as they’re talking about us. GLTA.
(6)
(0)
